Pretransplant pharmacodynamic analysis of immunosuppressive agents using CFSE-based T-cell proliferation assay

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 3, 2009, Pages 285-289

  Kurata, Y ^a,b   Kato, M ^b,c   Kuzuya, T ^b   Miwa, Y ^b   Iwasaki, K ^b   Haneda, M ^b   Amioka, K ^a   Watarai, Y ^d   Uchida, K ^d   Nakao, A ^b   Kobayashi, T ^b  

^a KINJO GAKUIN UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c MEIJO UNIVERSITY   (Japan)

^d NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; HUMAN; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; CELL PROLIFERATION; CYCLOSPORINE; FEMALE; FLUORESCEINS; FLUORESCENT DYES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREDNISOLONE; PROSPECTIVE STUDIES; SUCCINIMIDES; T-LYMPHOCYTES; TACROLIMUS;

EID: 69549118444     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.61     Document Type: Article

References (27)

1. Le Meur, Y. et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am. J. Transplant. 7, 2496-2503 (2007). (Pubitemid 47566324)
2. van Gelder, T. et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 86, 1043-1051 (2008).
3. Härtel, C., Fricke, L., Schumacher, N., Kirchner, H. & Müller-Steinhardt, M. Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: a quantitative measure of the efficacy of cyclosporin A-based immunosuppression. Clin. Chem. 48, 2225-2231 (2002). (Pubitemid 35397566)
4. Sommerer, C., Giese, T., Schmidt, J., Meuer, S. & Zeier, M. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Transplantation 85, 15-21 (2008).
5. Brunet, M. et al. Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2). Int. Immunopharmacol. 3, 987-999 (2003). (Pubitemid 36694869)
6. Weimert, N.A., Derotte, M., Alloway, R.R., Woodle, E.S. & Vinks, A.A. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Ther. Drug Monit. 29, 141-149 (2007).
7. Blanchet, B. et al. Pharmacokinetic-pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period. Ther. Drug Monit. 30, 412-418 (2008).
8. Fukudo, M. et al. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. Clin. Pharmacol. Ther. 78, 168-181 (2005). (Pubitemid 41112285)
9. Sugiyama, K., Satoh, H., Saito, K., Takahashi, K., Saito, N. & Hirano, T. Immunosuppressive efficacy of mycophenolate mofetil when compared with azathioprine and mizoribine against peripheral lymphocytes from renal transplant recipients. Transpl. Int. 18, 590-595 (2005). (Pubitemid 41726863)
10. Hirano, T. Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine. Int. Immunopharmacol. 7, 3-22 (2007). (Pubitemid 44856394)
11. Böhler, T. et al. Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Ther. Drug Monit. 29, 77-86 (2007). (Pubitemid 46279880)
12. Barten, M.J. et al. Pharmacodynamics of T-cell function for monitoring immunosuppression. Cell Prolif. 40, 50-63 (2007).
13. Knight, S.R. & Morris, P.J. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 85, 1675-1685 (2008).
14. Couzi, L., Thiébaut, R., Carron, J.C., Moreau, J.F., Merville, P. & Taupin, J.L. Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients. Transplantation 86, 1060-1067 (2008).
15. Lyons, A.B. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J. Immunol. Methods 243, 147-154 (2000).
16. Tanaka, Y. et al. Low incidence of acute rejection after living-donor liver transplantation: immunologic analyses by mixed lymphocyte reaction using a carboxyfluorescein diacetate succinimidyl ester labeling technique. Transplantation 79, 1262-1267 (2005). (Pubitemid 40664036)
17. Halloran, P.F., Helms, L.M., Kung, L. & Noujaim, J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 68, 1356-1361 (1999).
18. Kung, L. & Halloran, P.F. Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplantation 70, 327-335 (2000). (Pubitemid 30602753)
19. Budde, K. et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am. J. Transplant. 7, 888-898 (2007). (Pubitemid 46189596)
20. Bremer, S. et al. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression. Transplantation 85, 55-61 (2008).
21. Glander, P. et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am. J. Transplant. 4, 2045-2051 (2004). (Pubitemid 39611633)
22. Berry, V., Magill, A., Yost, M., Janosky, J. & Sindhi, R. Individualizing combination of two antiproliferative immunosuppressants with pharmacodynamic modeling of stimulated lymphocyte responses. Cytometry A 69, 95-103 (2006).
23. Shaw, L.M., Korecka, M., Venkataramanan, R., Goldberg, L., Bloom, R. & Brayman, K.L. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am. J. Transplant. 3, 534-542 (2003). (Pubitemid 36612836)
24. Batiuk, T.D., Urmson, J., Vincent, D., Yatscoff, R.W. & Halloran, P.F. Quantitating immunosuppression. Estimating the 50% inhibitory concentration for in vivo cyclosporine in mice. Transplantation 61, 1618-1624 (1996). (Pubitemid 26190904)
25. Bîrsan, T., Dambrin, C., Freitag, D.G., Yatscoff, R.W. & Morris, R.E. The novel calcineurin inhibitor ISA247: a more potent immunosuppressant than cyclosporine in vitro. Transpl. Int. 17, 767-771 (2005). (Pubitemid 41187416)
26. du Toit, E.A. & Rautenbach, M. A sensitive standardised micro-gel well diffusion assay for the determination of antimicrobial activity. J. Microbiol. Methods 42, 159-165 (2000).
27. Sato, M., Hutchinson, D.S., Evans, B.A. & Summers, R.J. The β3-adrenoceptor agonist 4-[[(Hexylamino)carbonyl]amino]-N-[4-[2-[[(2S)-2- hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-phenyl]-benzenesulfonamide (L755507) and antagonist (S)-N-[4-[2-[[3-[3-(acetamidomethyl)phenoxy]-2- hydroxypropyl]amino]-ethyl]phenyl]benzenesulfonamide (L748337) activate different signaling pathways in Chinese hamster ovary-K1 cells stably expressing the human β3-adrenoceptor. Mol. Pharmacol. 74, 1417-1428 (2008).